Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.45 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7241770 | 1.00 | TACR1 (0.46) | TACR1PTPN1MBTPS1PPARGSCN9A | |
| SCHEMBL7247047 | 0.93 | TACR1 (0.46) | TACR1PTPN1MBTPS1PPARGSCN9A | |
| SCHEMBL7247050 | 0.93 | TACR1 (0.46) | TACR1PTPN1MBTPS1PPARGSCN9A | |
| SCHEMBL7239314 | 0.91 | TACR1 (0.48) | TACR1PTPN1MBTPS1PPARGSCN9A | |
| SCHEMBL7239303 | 0.91 | TACR1 (0.48) | TACR1PTPN1MBTPS1PPARGSCN9A | |
| SCHEMBL6573594 | 0.89 | PTPN1 (0.49) | TACR1PTPN1MBTPS1PPARAACE | |
| SCHEMBL7240680 | 0.86 | PTPN1 (0.47) | TACR1PTPN1MBTPS1PPARAACE | |
| SCHEMBL7240686 | 0.86 | PTPN1 (0.47) | TACR1PTPN1MBTPS1PPARAACE | |
| SCHEMBL7676458 | 0.86 | PTPN1 (0.52) | TACR1PTPN1MBTPS1PPARAACE | |
| SCHEMBL31725913 | 0.82 | HDAC8 (0.55) | PTPN1PPARAMAPTKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6573295-B2 | Treating proliferative diseases, cancer, restenosis, osteoporosis, inflammation, aIlergies, or cardiovascular disease. | ARIAD PHARMACEUTICALS, INC. | 2003-06-03 | — | — | US | disclosed |
| US-6482852-B2 | UE TREATING PROLIFERATIVE DISEASE, CANCER, RESTENOSIS, OSTEOPOROSIS, INFLAMMATION, ALLERGIES, OR CARDIOVASCULAR DISEASE; INHIBITION OF SH2-MEDIATED SIGNALING | ARIAD PHARMACEUTICALS, INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020137941-A1 | Ue treating proliferative disease, cancer, restenosis, osteoporosis, inflammation, allergies, or cardiovascular disease; inhibition of SH2-mediated signaling | ARIAD PHARMACEUTICALS, INC. | 2002-09-26 | — | — | US | disclosed |
| US-20020062031-A1 | Bicyclic signal transduction inhibitors, compositions containing them & uses thereof | SHAKESPEARE WILLIAM C (US) | 2002-05-23 | — | — | US | disclosed |
| EP-1129068-A1 | BICYCLIC SIGNAL TRANSDUCTION INHIBITORS, COMPOSITION CONTAINING THEM AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027802-A1 | BICYCLIC SIGNAL TRANSDUCTION INHIBITORS, COMPOSITIONS CONTAINING THEM & USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020062031-A1 | Bicyclic signal transduction inhibitors, compositions containing them & uses thereof | ACP1, SRC, PPM1G | TACR1 3620/4885PTPN1 99/4885MBTPS1 1148/4885 |
| US-20020137941-A1 | Ue treating proliferative disease, cancer, restenosis, osteoporosis, inflammation, allergies, or cardiovascular disease; inhibition of SH2-mediated signaling | GRB2, LCK, PTK2 | TACR1 1577/4885PTPN1 55/4885MBTPS1 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.